Abstract
Graves’ orbitopathy (GO) is the most common cause of orbital tissue inflammation, accounting for ~ 60% of all orbital inflammatory conditions in the population aged 21–60 years, and for ~ 40% in the population aged > 60 year. GO is observed in 25–30% of patients with Graves’ hyperthyroidism and more rarely in association with hypothyroid autoimmune thyroiditis. In addition, a small proportion of GO patients (1–2%) do not have a clinically overt thyroid dysfunction. Clinically, GO is characterized by proptosis, inflammation involving the eyelids and the conjunctiva, extraocular muscle hypertrophy, with consequent reduction of ocular motility and diplopia, and in the most severe cases, compression of the optic nerves at the orbital apex, with reduction of visual acuity. At CT scan or MRI, a muscle increase involving the superior, medial and inferior rectus is quite typical. In the most severe forms, compression of the optic nerves at the orbital apex can be observed. Euthyroid GO is usually an early sign of a full-blown Graves’ disease; however, in some cases, the orbital disease can remain isolated. Moreover, euthyroid GO can rarely be unilateral, which makes the picture even more confusing. Under those circumstances, the diagnostic process becomes obviously quite difficult, having other conditions mimicking GO been excluded. A number of inflammatory conditions affecting orbital tissue can mimic GO, thereby requiring an accurate evaluation for a proper differential diagnosis. The majority of these conditions are immune mediated. Most of them are benign, but they can be rather aggressive and some can cause visual loss. The most common inflammatory condition affecting orbital tissues and mimicking GO is idiopathic orbital inflammation. Other, more rare, orbital diseases that should be considered in the differential diagnosis are infections, orbital manifestations of systemic diseases, primitive and secondary orbital neoplasms, and orbital vascular alterations. In most instances, when an orbitopathy occurs in the absence of hyperthyroidism, the diagnosis of the disease underlying the ocular symptoms and signs is based on exclusion of the other conditions. Here we review the conditions that can mimic GO and how to distinguish them from this obnoxious eye disease.
Similar content being viewed by others
References
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ Orbitopathy. Eur Thyroid J 5:9–26
Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449
Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Role of the underlying thyroid disease on the phenotype of Graves’ orbitopathy in a tertiary referral center. Thyroid 25:347–351
Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A (1989) Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 120:473–478
Bahn RS (2015) Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778
Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A (2004) Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 2004(27):230–236
Rodia C, Menconi F, Mazoni L, Torregrossa L, Basolo F, Vitti P, Marcocci C, Marinò M (2019) A case of unilateral dermopathy possibly related to Graves’ disease. Eur Thyroid J 8:278–282 (in press)
Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, Menconi F, Piaggi P, Sellari-Franceschini S, Nardi M, Latrofa F, Vitti P, Marcocci C, Basolo F, Marinò M (2018) Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy. JAMA Ophthalmol 136:613–619
Rotondo Dottore G, Leo M, Casini G, Latrofa F, Cestari L, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2017) Anti-oxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves’ orbitopathy. Thyroid 27:271–278
Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ Orbitopathy (GO): a new frontier for GO treatment? J Endocrinol Invest 41:193–201
Rotondo Dottore G, Ionni I, Menconi F, Casini G, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO). J Endocrinol Invest 41:815–820
Smith TJ, Janssen JAMJL (2019) Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev 40:236–267
Marinò M, Rotondo Dottore G, Ionni I, Lanzolla G, Sabini E, Ricci D, Sframeli A, Mazzi B, Menconi F, Latrofa F, Vitti P, Marcocci C, Chiovato L (2019) Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest 42:471–480
Bartalena L, Pinchera A, Marcocci C (2000) Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 21:168–199
Dolman PJ (2012) Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 26:229–248
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves’ Orbitopathy (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364:1920–1931
Marinò M, Menconi F, Rotondo Dottore G, Leo M, Marcocci C (2018) Selenium in Graves’ Hyperthyroidism and Orbitopathy. Ophthal Plast Reconstr Surg 34(4S Suppl 1):S105–S110
Marinò M, Dottore GR, Leo M, Marcocci C (2018) Mechanistic pathways of selenium in treatment for Graves’ disease and Graves’ orbitopathy. Horm Metab Res 50:887–893
Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ, European Group on Graves’ Orbitopathy (EUGOGO) (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:547–553
Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Long term outcome of Graves’ orbitopathy following high dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661–668
Stan MN, Salvi M (2016) Management of endocrine diseASE: Rituximab therapy for Graves’ orbitopathy—lessons from randomized control trials. Eur J Endocrinol 176:R101–R109
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761
Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:885–887
Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287–298
Pérez-Moreiras JV, Alvarez-López A, Gómez EC (2014) Treatment of active corticosteroid-resistant Graves’ Orbitopathy. Ophthalmic Plast Reconstr Surg 30:162–167
Sellari-Franceschini S, Rocchi R, Marinò M, Bajraktari A, Mazzi B, Fiacchini G, Lepri P, Dallan I, Vitti P, Marcocci C (2018) Rehabilitative orbital decompression for Graves’ Orbitopathy: results of a randomized clinical trial. J Endocrinol Invest 41:1037–1042
Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Currò N, Konuk O, Marinò M, Mitchell AL, Stankovic B, Törüner FB, von Arx G, Zarković M, Wiersinga WM (2017) Graves’ orbitopathy as a rare disease in Europe: a European Group On Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72
Yeşiltaş YS, Gündüz AK (2018) Idiopathic orbital inflammation: review of literature and new advances. Middle East Afr J Ophthalmol 25:71–80
Patnana M, Sevrukov AB, Elsayes KM, Viswanathan C, Lubner M, Menias CO (2012) Inflammatory pseudotumor: the great mimicker. Am J Roentgenol 198:W217–W227
Chang JR, Gruener AM, McCulley TJ (2017) Orbital disease in neuro-ophthalmology. Neurol Clin 35:125–144
Ding ZX, Lip G, Chong V (2011) Idiopathic orbital pseudotumour. Clin Radiol 66:886–892
Montagnese F, Wenninger S, Schoser B (2016) “Orbiting around” the orbital myositis: clinical features, differential diagnosis and therapy. J Neurol 263:631–640
Yan J, Wu P (2014) Idiopathic orbital myositis. J Craniofac Surg 25:884–887
Gündüz AK, Yeşiltaş YS, Shields CL (2018) Overview of benign and malignant lacrimal gland tumors. Curr Opin Ophthalmol 29:458–468
Pakdaman MN, Sepahdari AR, Elkhamary SM (2014) Orbital inflammatory disease: pictorial review and differential diagnosis. World J Radiol 6:106–115
Hickman SJ (2016) Optic perineuritis. Curr Neurol Neurosci Rep 16:16
Mombaerts I, Bilyk JR, Rose GE, McNab AA, Fay A, Dolman PJ, Allen RC, Devoto MH, Harris GJ, Expert Panel of the Orbital Society (2017) Expert Panel of the Orbital Society. Consensus on Diagnostic Criteria of Idiopathic Orbital inflammation using a modified delphi approach. JAMA Ophthalmol 135:769–776
Yuen SJ, Rubin PA (2003) Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophtalmol 121:491–499
Weber AL, Romo LV, Sabates NR (1999) Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. Radiol Clin N Am 37:151–168
Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336:1224–1234
Thomas KW, Hunninghake GW (2003) Sarcoidosis. JAMA 289:3300–3303
Pasoto SG, de Oliveira Adriano, Martins V, Bonfa E (2019) Sjögren’s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol 11:33–45
Bhatia A, Yadava U, Goyal JL, Chaturvedi KU (2005) Limited Wegener’s granulomatosis of the orbit: a case study and review of literature. Eye 19:102–104
Lutt JR, Lim LL, Phal PM, Rosenbaum JT (2008) Orbital inflammatory disease. Semin Arthritis Rheum 37:207–222
Olsen TG, Heegaard S (2018) Orbital lymphoma. Surv Ophthalmol 64:45–66
Kasliwal MK, Suri A, Gupta DK, Suri V, Rishi A, Sharma BS (2008) Sphenoid wing inflammatory pseudotumor mimicking a clinoidal meningioma: case report and review of the literature. Surg Neurol 70:509–513
Saeed P, Rootman J, Nugent RA, White VA, Mackenzie IR, Koornneef L (2003) Optic nerve sheath meningiomas. Ophtalmology 110:2019–2030
Sullivan TJ (2018) Vascular anomalies of the orbit-A reappraisal. Asia Pac J Ophthalmol (Phila) 7:356–363
Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 66:539–551
Rotondi M, Carbone A, Coperchini F, Fonte R, Chiovato L (2019) Diagnosis of Endocrine disease: IgG4-related thyroid autoimmune disease. Eur J Endocrinol 180:R175–R183
Bartalena L, Chiovato L (2014) Graves’-like orbitopathy: do not forget IgG4-related disease. J Endocrinol Invest 37:1233–1235
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the individual participant included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Marinò, M., Ionni, I., Lanzolla, G. et al. Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest 43, 401–411 (2020). https://doi.org/10.1007/s40618-019-01141-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-019-01141-3